BCAB

Conviction 31HealthcareScan · Mon, Aug 10, 2026

BCAB$3.46+0.00%

ResistanceSupportVol 14

Vol MA14 32.15K

May 11May 28Jun 16Jul 6Jul 23Aug 10

BioAtla, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.bioatla.com ↗

Price3.46

Change+0.00%

Gap+3.18%

Rel volume0.36×

Avg volume32.66K

Avg $ vol116.27K

SMA 203.54

SMA 503.65

SMA 2002.03

Price vs 50-5.12%

Price vs 200+70.73%

MA stackmixed

50/200 cross—

Supertrenddown · 4.20

RSI (14)47

MACD hist0.00

MACD crossbull · 0d

Stoch %K / %D56 / 40

ADX (14)14

+DI / −DI20 / 13

RSI divergence—

MACD divergence—

ATR %+9.13%

ADR %8.10%

52w high5.84

52w low0.1304

From 52w high-40.75%

Above 52w low+2553.37%

New 52w highNo

SqueezeOff

Bollinger width32.84%

%B0.43

Donchian pos27.68%

Donchian high4.27

Donchian low3.15

AVWAP (52w high)4.08

vs AVWAP high-15.23%

AVWAP (52w low)2.18

vs AVWAP low+58.39%

OBV trendFlat

Chaikin MF (20)-0.07

Today vs 20d0.36×

Avg vol (14d)32.15K

Avg vol (20d)32.66K

Avg $ vol (20d)116.27K

Market cap111.81M

RS 3m (vs SPY)-26.16%

RS 6m (vs SPY)+1705.98%

RS line new highNo

Trend template5/8

Technical rank69.0

1 week+6.13%

1 month-9.42%

3 months-28.51%

6 months+1542.92%

1 year+810.77%

YTD+547.70%

P/E-1.88

P/B-3.00

P/S372.70

P/FCF—

EPS-1.01

Div yield—

ROE159.77%

ROA—

Debt/Eq—

Current0.15

EV/EBITDA-1.86

Gross margin—

Net margin—

Rev growth0.00%

EPS growth14.57%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value109.85M

Revenue0

Net income-6.34M

Gross profit—

Free cash flow—

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out—

Employees41

ListedWed, Dec 16, 2020

Free float60.28M

Float %81.2%

Short interest123.94K

Days to cover1.9d

Short volume39.7%

Squeeze score10 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction31 / 100

Pattern quality—

Tech rank69.0 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance4.50

Support3.18

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BCAB

All disclosures →

No recent disclosed trades by Congress in BCAB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BCAB · 6 sells

Insider	Side	Shares	Value	Traded	Filed
Sievers Eric Chief Medical Officer · Common Stock · 2026-05-31	Tax	134	$527	2026-05-31	2026-06-05
SHORT JAY M PHD Chief Executive Officer · Common Stock · 2026-05-31	Tax	259	$1K	2026-05-31	2026-06-05
Vasquez Christian Chief Financial Officer · Common Stock · 2026-05-31	Tax	82	$322	2026-05-31	2026-06-05
SHORT JAY M PHD Chief Executive Officer · Common Stock · 2026-03-12	Tax	639	$107	2026-03-12	2026-06-05
SHORT JAY M PHD Chief Executive Officer · Common Stock · 2026-03-12	Other	—	—	2026-03-12	2026-06-05
Sievers Eric Chief Medical Officer · Common Stock · 2026-03-11	Tax	360	$61	2026-03-11	2026-06-05
Vasquez Christian Chief Financial Officer · Common Stock · 2026-03-11	Tax	175	$30	2026-03-11	2026-06-05

SEC filings

EDGAR filings in BCAB · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.